Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transthyretin alters cardiac fibroblast structure, function and inflammatory gene expression.

ABSTRACT: Transthyretin alters cardiac fibroblast structure, function and inflammatory gene expression.

PROVIDER: PRJNA734300 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14701431.fastq.gz	Fastqsanger.gz
	SRR14701432.fastq.gz	Fastqsanger.gz
	SRR14701433.fastq.gz	Fastqsanger.gz
	SRR14701434.fastq.gz	Fastqsanger.gz
	SRR14701435.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Transthyretin alters cardiac fibroblast structure, function and inflammatory gene expression.

Project description:Age-related wild type transthyretin amyloidosis (wtATTR) is characterized by systemic deposition of amyloidogenic fibrils of misfolded transthyretin (TTR) in the connective tissue of many organs. In the heart this leads to cardiac dysfunction, which is a significant cause of age-related heart failure. The hypothesis tested is that TTR affects cardiac fibroblasts in ways that may contribute to fibrosis. When primary cardiac fibroblasts were cultured on TTR-deposited substrates, the F-actin cytoskeleton disorganized, focal adhesion formation decreased, and nuclear shape was flattened. Fibroblasts had faster collective and single cell migration velocities on TTR-deposited substrates. Additionally, fibroblasts cultured on microposts with TTR deposition had reduced attachment and increased proliferation above untreated. Transcriptomic and proteomic analyses of fibroblasts grown on glass covered with TTR showed significant upregulation of inflammatory genes after 48 hours, indicative of progression in TTR-based diseases. Together, results suggest that TTR deposited in tissue extracellular matrix may affect both the structure, function and gene expression of cardiac fibroblasts. As therapies for wtATTR are cost-prohibitive and only slow disease progression, better understanding of cellular maladaptation may elucidate novel therapeutic targets.

2021-06-02 | GSE175917 | GEO

TEAD1 in cardiac fibroblast activation

Project description:TEAD1 in cardiac fibroblast activation

| PRJNA1064074 | ENA

Pregestational Diabetes Alters Cardiac changes

Project description:Pregestational Diabetes Alters Cardiac changes

| PRJNA804008 | ENA

Targeting Immune-Fibroblast Crosstalk in Myocardial Infarction and Cardiac Fibrosis II

Project description:To examine whether commonly used human cultured fibroblast systems model human cardiac fibroblasts, we tested three different fibroblast cell preparations: primary human cardiac fibroblasts (NHCF), human dermal fibroblasts (NHDF), and immortalized human cardiac fibroblasts (iHCF).

2024-07-01 | GSE218391 | GEO

A cardiac fibroblast-enriched micropeptide regulates inflammation

Project description:A cardiac fibroblast-enriched micropeptide regulates inflammation

| PRJNA1105958 | ENA

Hedgehog signaling alters the balance of fibroblast subtypes in pancreatic cancer [scRNA-seq]

Project description:A better understanding of the roles of signaling pathways differentially activated in distinct fibroblast populations will shed light on the complexity of fibroblast heterogeneity in pancreatic cancer. Here, we show that Hedgehog pathway inhibition alters the fibroblast composition towards a more inflammatory microenvironment, opening the possibility for future combination therapies.

2021-02-01 | GSE156438 | GEO

Hedgehog signaling alters the balance of fibroblast subtypes in pancreatic cancer [bulk RNA-seq]

2021-02-01 | GSE156866 | GEO

AP-1 signaling modulates cardiac fibroblast stress responses

Project description:AP-1 signaling modulates cardiac fibroblast stress responses

| PRJNA937247 | ENA

Amyloid beta 42 alters cardiac metabolism and impairs cardiac function in obesity

Project description:Amyloid beta 42 alters cardiac metabolism and impairs cardiac function in obesity

| PRJNA882101 | ENA

Transcriptomic profiling of normal human cardiac fibroblast treated with halofuginone

Project description:Normal human cardiac fibroblast were treated with 200 nM halofuginone for 24 hours and the transcriptomic profile was measured by RNAseq.

2017-03-03 | GSE95059 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data